Holen Sie sich die Stockscreener-App
29.85
0.23%
-0.07
Handel nachbörslich:
29.85
Schlusskurs vom Vortag:
$29.92
Offen:
$29.97
24-Stunden-Volumen:
854.44K
Relative Volume:
5.31
Marktkapitalisierung:
$369.64M
Einnahmen:
$9.71M
Nettoeinkommen (Verlust:
$-29.96M
KGV:
-8.5776
EPS:
-3.48
Netto-Cashflow:
$-14.79M
1W Leistung:
+6.65%
1M Leistung:
-6.95%
6M Leistung:
+7.72%
1J Leistung:
+15.97%
1-Tages-Spanne:
$29.14
$30.79
1-Wochen-Bereich:
$25.30
$30.79
52-Wochen-Spanne:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Firmenname
Xoma Royalty Corp
Sektor
Branche
Telefon
510-204-7239
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Vergleichen Sie XOMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
29.85 | 370.50M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | The Benchmark Company | Buy |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2021-09-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-06-29 | Eingeleitet | Aegis Capital | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2017-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-11 | Bestätigt | Wedbush | Outperform |
| 2015-07-23 | Herabstufung | Jefferies | Buy → Hold |
| 2015-07-22 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Fortgesetzt | ROTH Capital | Buy |
| 2014-04-29 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-11 | Herabstufung | MLV & Co | Buy → Hold |
| 2014-03-05 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-10-31 | Bestätigt | MLV & Co | Buy |
| 2013-05-09 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-14 | Eingeleitet | Cowen & Co | Outperform |
| 2011-03-31 | Bestätigt | MLV Capital | Buy |
| 2011-03-23 | Bestätigt | RBC Capital Mkts | Outperform |
| 2011-01-06 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-01-04 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - ulpravda.ru
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com
XOMA Royalty: Entitled to Payments Associated - 富途牛牛
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat
XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm
XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative
Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire
Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st
FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
Xoma announces closing of transactions to acquire Lava Therapeutics - MSN
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com Canada
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday?Rezolute (NASDAQ:RZLT), XOMA Royalty (NASDAQ:XOMA) - Benzinga
Two Biotechs Crash, One Down 87%, On Failed Insulin Drug - Investor's Business Daily
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
XOMA Royalty Corp CEO Owen Hughes Acquires 100,000 Depositary Shares - TradingView — Track All Markets
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA (NASDAQ:XOMAO) Trading 0.8% Higher – Time to Buy? - Defense World
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):